SCHEMBL735348

SCHEMBL735348

O=CCCN1CCN(c2cccc(C(F)(F)F)c2)CCC1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 6/20 0.54
DRD3 P35462 4/20 0.48
DRD1 P21728 2/20 0.48
HTR1A P08908 1/20 0.48
SIGMAR1 Q99720 2/20 0.48
ALDH1A1 P00352 3/20 0.47
HTR3E A5X5Y0 1/20 0.47
HTR3B O95264 1/20 0.47
HTR1D P28221 1/20 0.47
HTR2C P28335 1/20 0.47
HTR3A P46098 1/20 0.47
HTR3D Q70Z44 1/20 0.47
HTR3C Q8WXA8 1/20 0.47
DRD2 P14416 2/20 0.47
DRD5 P21918 2/20 0.47
MAPT P10636 3/20 0.46
THRB P10828 1/20 0.46
KDM4E B2RXH2 1/20 0.46
LMNA P02545 1/20 0.46
MDM2 Q00987 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL734497 0.90 HTR7 (0.53) HTR7DRD3DRD1HTR1ASIGMAR1
SCHEMBL734048 0.81 HTR7 (0.65) HTR7DRD3DRD1SIGMAR1DRD2
SCHEMBL734563 0.79 HTR7 (0.60) HTR7DRD3DRD1HTR1ADRD2
SCHEMBL3660752 0.75 ALDH1A1 (0.64) HTR7SIGMAR1ALDH1A1HTR3EHTR3B
SCHEMBL5178743 0.75 HTR7 (0.72) HTR7DRD3DRD1HTR1ASIGMAR1
SCHEMBL1733940 0.75 SIGMAR1 (0.60) HTR7HTR1ASIGMAR1ALDH1A1HTR3E
SCHEMBL736301 0.75 POLB (0.48) HTR7ALDH1A1MAPTLMNA
SCHEMBL736300 0.75 POLB (0.48) HTR7ALDH1A1MAPTLMNA
SCHEMBL28226906 0.75 ALDH1A1 (0.77) HTR1ASIGMAR1ALDH1A1HTR3EHTR3B
SCHEMBL9581047 0.74 HTR7 (0.71) HTR7DRD3DRD1HTR1ASIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
EP-2321285-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
WO-2010012619-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 HTR7 408/4885DRD3 165/4885DRD1 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.